Authored By: Sarah
17 Aug 2024

Sinusitis Drugs Market 2023-2027: Size and Surgical intervention used for sinusitis management; growth driven by the Product, Some of key Companies Positioned Strategically

The sinusitis drugs market size by Product (Steroid nasal sprays, Antibiotics, Decongestants, and Other drugs) and Geography (North America, Europe, Asia, and Rest of World (ROW)), is forecast to increase by USD 801.39 million. The market is expected to grow at a CAGR of  over 6.23% between 2023 and 2027.

  • In the sinusitis drugs market, functional endoscopic sinus surgery (FESS) holds a significant position as the preferred treatment for chronic rhinosinusitis. According to a study by Bunzen DL et al., FESS led to a 54.2% (13 out of 24 patients) overall improvement rate in patients with chronic rhinosinusitis and nasal polyps. This surgical approach has been validated through numerous studies, demonstrating its efficacy in alleviating symptoms related to chronic rhinosinusitis.
  • The largest segment in the global sinusitis drugs market, accounting for 40.00% of the market share in 2022, is characterized by significant investment in research and development (R&D) by leading pharmaceutical companies. Regulatory frameworks in this region facilitate the approval of new drugs, with Pfizer currently conducting Phase I trials for PF-06817024, an investigational biologic for chronic rhinosinusitis with nasal polyps and atopic dermatitis. Optinose US Inc. is similarly progressing Phase III clinical trials for OPN-375 in the treatment of chronic sinusitis. Keywords: Sinusitis Drugs Market, Global Market Share, Research and Development, Pharmaceutical Companies, Regulatory Frameworks, Pfizer, PF-06817024, Chronic Rhinosinusitis, Atopic Dermatitis, Optinose US Inc., OPN-375.

Access the full report to know who are the other key countries segment-wise forecast and historic data

 

Some of the Key Companies:

  • AbbVie Inc.
  • Alembic Pharmaceuticals Ltd.
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Bionpharma Inc.
  • CHIESI Farmaceutici SpA
  • Cipla Ltd.
  • Dr Reddys Laboratories Ltd.
  • Fresenius SE and Co. KGaA
  • GlaxoSmithKline Plc
  • Hikma Pharmaceuticals Plc
  • Johnson and Johnson
  • Merck and Co. Inc.
  • Neopharma Corp.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teligent Inc.
  • Teva Pharmaceutical Industries Ltd.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio